

PERSONAL INFORMATION

CARLO ALBERTO GIORGI

 +39 049 8215931

 carloalberto.giorgi@ioveneto.it

Date of birth 07 Janury 1984 | Nationality Italian

WORK EXPERIENCE

07/2015–Present

Research fellow

University of Padova
Dipartimento di Scienze Chirurgiche, Oncologiche e Gastroenterologiche
Istituto Oncologico Veneto IRCCS Oncologia Medica 2

07/2015–Present

Medical Oncologist

Istituto Oncologico Veneto, IOV - Medical Oncology 2 Unit, Padova (Italy)
Medical Oncologist with special interest in breast cancer

05/2010–05/2015

Resident in Medical Oncology

Università degli Studi di Padova, Istituto Oncologico Veneto, Medical Oncology 2, Padova (Italy)
Clinical activity and clinical research in Medical Oncology, in particular in the field of Breast cancer
Business or sector Breast cancer

EDUCATION AND TRAINING

06/2011–06/2016

Residency in Medical Oncology

Università degli Studi di Padova, Padova (Italy)
Degree achieved on the 19th May 2015.
Final evaluation: 110/110 cum laude.

10/2003–07/2009

Medical Degree

Università degli Studi di Padova
Degree achieved on the 27th July 2010.
Final evaluation: 110/110 cum laude.

09/1998–07/2003

Maturità Scientifica

Liceo Statale G:B Ferrari, Este (PD)

Mother tongue Italian

Other languages	UNDERSTANDING		SPEAKING	
	Listening	Reading	Spoken interaction	Spoken production
Inglese	C1	C1	C1	C1
Tedesco	B1	B1	B1	B1

Levels: A1 and A2: Basic user - B1 and B2: Independent user - C1 and C2: Proficient user
Common European Framework of Reference for Languages

ADDITIONAL INFORMATION

Trial Experience

Experience in clinical trial under GCP.

GCP and study management training completed on 29 OCT 2013.

Publications

Complete response to weekly carboplatin-docetaxel chemotherapy in a 91-year-old woman with anaplastic thyroid cancer. Am J Otolaryngol. 2015 Mar-Apr;36(2):268-72.

Electrochemotherapy in non-melanoma head and neck cancers: a retrospective analysis of the treated cases. Br J Oral Maxillofac Surg. 2014 Dec;52(10):957-64.

Late onset (22 years) of simultaneous tonsillar and cervical lymph node metastases from breast ductal carcinoma. Am J Otolaryngol. 2012 Sep-Oct;33(5):627-30

Cross-talk between chronic lymphocytic leukemia (CLL) tumor B cells and mesenchymal stromal cells (MSCs): implications for neoplastic cell survival. Oncotarget. 2015 Dec 8;6(39).

Targeted therapies for HER2 positive breast cancer. Capitolo di "Targeted Therapies for Solid Tumors", Current Clinical Pathology 2015, pp 57-72

Beyond Breast specific - Graded Prognostic Assessment in patients with brain metastases from breast cancer: treatment impact on outcome. J Neurooncol 2016, Nov. epub.